Drug intelligence / Profile preview

botulinum toxin A + triamcinolone acetonide

Development stage: Preclinical
Lead developer: AbbVie
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intralesional

Overview

A combination therapy using botulinum toxin A and triamcinolone acetonide primarily for treating hypertrophic scars and keloids. Botulinum toxin A blocks neuromuscular transmission by inhibiting acetylcholine release, while triamcinolone acetonide is a corticosteroid with anti-inflammatory properties. The combination has shown enhanced efficacy in reducing scar-related symptoms like pain and itching compared to either component alone.

Other names: BTA + TCATAC/BTX-ABTX-A + TCABTA + TAC

Targets

GR (Glucocorticoid receptor)SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on botulinum toxin A + triamcinolone acetonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on botulinum toxin A + triamcinolone acetonide.

Explore the full profile